+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Division Protein FtsZ (ftsz) - Drugs In Development, 2021

  • ID: 5359610
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 36 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Pedanius Therapeutics Ltd
  • TAXIS Pharmaceuticals Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds GTP and shows GTPase activity.

Cell Division Protein FtsZ (ftsz) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Staphylococcus aureus Infections, Tuberculosis, Acinetobacter Infections, Bacillus Infections, Bacterial Pneumonia, Enterococcus faecium Infections, Skin and Skin Structure Infections (SSSI) Caused By Bacteria, Streptococcal Pneumonia, Vancomycin-Resistant Enterococcus faecium Infections and Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections.

The latest report Cell Division Protein FtsZ - Drugs In Development, 2021, outlays comprehensive information on the Cell Division Protein FtsZ (ftsz) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz)
  • The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsz) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Pedanius Therapeutics Ltd
  • TAXIS Pharmaceuticals Inc
Introduction
  • Report Coverage
Cell Division Protein FtsZ (ftsz) - Overview

Cell Division Protein FtsZ (ftsz) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Cell Division Protein FtsZ (ftsz) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Cell Division Protein FtsZ (ftsz) - Companies Involved in Therapeutics Development
  • Pedanius Therapeutics Ltd
  • TAXIS Pharmaceuticals Inc
Cell Division Protein FtsZ (ftsz) - Drug Profiles

PED-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SBP-17GA20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit FtsZ for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit FtsZ for Streptococcal Pneumonia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
TXA-709 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Cell Division Protein FtsZ (ftsz) - Dormant Products

Cell Division Protein FtsZ (ftsz) - Product Development Milestones

Featured News & Press Releases
  • Dec 13, 2019: Pedanius Therapeutics FtsZ Programme demonstrates in vivo efficacy in pneumonia caused by Acinetobacter baumannii
  • Sep 07, 2016: FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic:
  • Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection
  • Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination
  • Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance
  • Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Pedanius Therapeutics Ltd, 2021
  • Pipeline by TAXIS Pharmaceuticals Inc, 2021
  • Dormant Projects, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Pedanius Therapeutics Ltd
  • TAXIS Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll